Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDD in colorectal cancer
NCT03272659Phase 2Withdrawn
- Sponsor
- Dr. Te Vuong
- Start
- Apr 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of hexaminolevulinate in colorectal cancer (CRC), sponsored by Dr. Te Vuong. Primary endpoint: Fluorescence with photodynamic diagnostics (PDD) in colorectal cancer at 9 months. Planned start Apr 2018; status: withdrawn.
02
Drugs
hexaminolevulinate
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03272659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272659.